Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More

Dr Sands on the Evolving Role of ADCs in SCLC Management

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes